المؤلفون: C. Dromain, M. E. Pavel, P. Ruszniewski, A. Langley, C. Massien, E. Baudin, M. E. Caplin, A. M. Raderer, B. I. Borbath, D. Ysebaert, E. Sedl('a)?kov('a), P. V('i)tek, D. H. Gr?nb?k, F. A. Adenis, L. Buscail, G. Cadiot, S. Dominguez, M. Ducreux, C. Lombard-Bohas, E. Mitry, J. F. Seitz, N. Begum, I. Harsch, M. Pavel, R. Cannizzaro, CLARINET Study Group

المساهمون: Dromain, C., Pavel, M. E., Ruszniewski, P., Langley, A., Massien, C., Baudin, E., Caplin, M. E., Raderer, A. M., Borbath, B. I., Ysebaert, D., Sedl('a)?kov('a), E., V('i)tek, P., Gr?nb?k, D. H., Adenis, F. A., Buscail, L., Cadiot, G., Dominguez, S., Ducreux, M., Lombard-Bohas, C., Mitry, E., Seitz, J. F., Begum, N., Harsch, I., Pavel, M., Cannizzaro, R., Study Group, Clarinet

مصطلحات موضوعية: Lanreotide, Neuroendocrine tumor, Prognostic factor, RECIST, Tumor growth rate, Disease Progression, Female, Human, Intestinal Neoplasm, Male, Neoplasm Grading, Neoplasm Staging, Pancreatic Neoplasm, Prognosi, Proportional Hazards Model, Tumor Burden

وصف الملف: ELETTRONICO

Relation: info:eu-repo/semantics/altIdentifier/pmid/30642293; info:eu-repo/semantics/altIdentifier/wos/WOS:000455576500003; volume:19; issue:1; firstpage:"-"; lastpage:"-"; numberofpages:9; journal:BMC CANCER; https://hdl.handle.net/11368/3056680; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85059955307; https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5257-x; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332566/

الاتاحة: https://hdl.handle.net/11368/3056680
https://doi.org/10.1186/s12885-018-5257-x
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5257-x
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332566/